Global GLP-1 Agonist Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global GLP-1 Agonist Market Insights, Forecast to 2034
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.
Global GLP-1 Agonist market is expected to reach to US$ 17800 million in 2024, with a positive growth of %, compared with US$ 20600 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, GLP-1 Agonist industry is evaluated to reach US$ 44730 million in 2034. The CAGR will be 16.6% during 2024 to 2034.
Globally, GLP-1 Agonist key manufacturers include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. Novo Nordisk, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of GLP-1 Agonist were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034 and the sales share will be % in 2034. Moreover, China, plays a key role in the whole GLP-1 Agonist market and estimated to attract more attentions from industry insiders and investors.
GLP-1 Agonist can be divided into Long-Acting Drug and Short-Acting Drug, etc. Long-Acting Drug is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2034.
GLP-1 Agonist is widely used in various fields, such as Diabetes, Obesity, Nonalcoholic Fatty Liver Disease and Metabolic Disorder, etc. Diabetes provides greatest supports to the GLP-1 Agonist industry development. In 2022, global % sales of GLP-1 Agonist went into Diabetes filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global GLP-1 Agonist market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global GLP-1 Agonist market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ GLP-1 Agonist plant distribution, commercial date of GLP-1 Agonist, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, GLP-1 Agonist introduction, etc. GLP-1 Agonist Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14QYResearch’s Conclusions of GLP-1 Agonist
Chapter 15Methodology and Data Sources adopted by QYResearch
Global GLP-1 Agonist market is expected to reach to US$ 17800 million in 2024, with a positive growth of %, compared with US$ 20600 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, GLP-1 Agonist industry is evaluated to reach US$ 44730 million in 2034. The CAGR will be 16.6% during 2024 to 2034.
Globally, GLP-1 Agonist key manufacturers include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. Novo Nordisk, AstraZeneca, Sanofi are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of GLP-1 Agonist were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034 and the sales share will be % in 2034. Moreover, China, plays a key role in the whole GLP-1 Agonist market and estimated to attract more attentions from industry insiders and investors.
GLP-1 Agonist can be divided into Long-Acting Drug and Short-Acting Drug, etc. Long-Acting Drug is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2034.
GLP-1 Agonist is widely used in various fields, such as Diabetes, Obesity, Nonalcoholic Fatty Liver Disease and Metabolic Disorder, etc. Diabetes provides greatest supports to the GLP-1 Agonist industry development. In 2022, global % sales of GLP-1 Agonist went into Diabetes filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global GLP-1 Agonist market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global GLP-1 Agonist market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
AstraZeneca
Sanofi
GSK
Eli Lilly
Zealand Pharma A/S
hansoh
BENEMAE
Segment by Type
Long-Acting Drug
Short-Acting Drug
Segment by Application
Diabetes
Obesity
Nonalcoholic Fatty Liver Disease
Metabolic Disorder
Alzheimer's Disease
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ GLP-1 Agonist plant distribution, commercial date of GLP-1 Agonist, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, GLP-1 Agonist introduction, etc. GLP-1 Agonist Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14QYResearch’s Conclusions of GLP-1 Agonist
Chapter 15Methodology and Data Sources adopted by QYResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices